GSK’s Pandemrix Swine Flu Vaccine- Pandora’s Box Release

OneClickGroup By Lara, Health Advocate

By Brocke TruthImage@Internode.On.Net

By Brocke TruthImage@Internode.On.Net

GlaxoSmithKline’s ‘Pandemrix’ H1N1 flu virus vaccine has been given a licence for use in Europe by regulatory agencies and the UK is now contracted to buy 60 million doses. This means that in just a few short weeks time the UK population, including babies as young as 6 months and pregnant women, may begin to receive the new vaccine.
The reason the H1N1 vaccine was able to receive such rapid approval is that for the last few years GSK, like many other vaccine manufacturers, have been developing and patenting ‘pandemic’ flu vaccines.
See Patent WO2006100109A1 to GSK Filed 21st March 2006
“In a preferred embodiment, the influenza strain may be associated with a pandemic outbreak or have the potential to be associated with a pandemic outbreak. In particular, when the vaccine is a multivalent vaccine such as a bivalent or a trivalent vaccine, at least one strain is associated with a pandemic outbreak or has the potential to be associated with a pandemic outbreak. Suitable strains are, but not limited to: H5N1, H9N2, H7N7, H2N2 and H1N1.”
“Example II-Preparation and characterization of the oil in water emulsion and adjuvant formulations. Unless otherwise stated, the oil/water emulsion used in the subsequent examples is composed an organic phase made of 2 oils (alpha-tocopherol and squalene), and an aqueous phase of PBS containing Tween 80 as emulsifying agent. Unless otherwise stated, the oil in water emulsion adjuvant formulations used in the subsequent examples were made comprising the following oil in water emulsion component (final concentrations given): 2.5% squalene (v/v), 2.5% alpha-tocopherol (v/v), 0.9% polyoxyethylene sorbitan monooleate (v/v) (Tween 80), see WO 95/17210. This emulsion, termed ASO3 in the subsequent examples, was prepared as followed as a two-fold concentrate”
GSK actually submitted an application for Marketing Authorisation Approval (MAA) for Pandemrix in February 2007 to the European Medicines Agency (EMEA). The application was for a ‘mock-up’ vaccine containing an H5N1 flu strain. This formulation was granted approval in May 2008. Now, the mock-up flu strain will be switched to the new pandemic H1N1 strain to produce the current pandemic vaccine. GSK’s timing in relation to the ‘swine flu’ outbreak, as with Baxter, was all but perfect.
Documentation associated with the application and approval can be found on the EMEA web site HERE
See CHMP ASSESSMENT REPORT
See PRODUCT INFORMATION
The documentation details the mock-up vaccine’s formulation:
Active Ingredient:
Purified antigen fractions of inactivated split virion
A/Vietnam/1194/2004 NIBRG-14 (H5N1) 3.75 μg HA (mock-up virus)
(NB – this will be switched to A/California/7/2009 (H1N1) v-like strain (X-179A) for the current pandemic vaccine)
Adjuvant:
Squalene 10.68 mg
Alpha-tocopherol 11.86 mg
Polysorbate 80 4.86 mg
Other Ingredients:
Octoxynol 10
Sodium chloride
Disodium phosphate
Potassium dihydrogen phosphate
Potassium chloride
Magnesium chloride
Thiomersal (5μg per dose)
Water for injections
As can be seen from this list, the vaccine contains the organomercury-based preservative ‘thiomersal’ (also known as thimerosal). In addition, the adjuvant includes the oil ‘squalene’. Both of these compounds have been associated with safety concerns, neurodegenerative and autoimmune illnesses. Thiomersal in particular has been removed or reduced in content in many vaccines both in Europe and the USA. Squalene is also a controversial compound, shown by a number of researchers to induce autoimmune disease in animals and has been linked to illness in Gulf War Veterans who were administered the Anthrax vaccine.
None of this is very comforting, and looking more closely at the CHMP documentation submitted to the EMEA, does nothing to inspire confidence in the GSK Pandemrix vaccine.
For instance, the reports detail:
“Safety pharmacology programme… No safety pharmacology
studies were performed with Pandemrix vaccine”
“Pharmacodynamic drug interactions…No studies were performed”
“Pharmacokinetics…Experimental studies to demonstrate absorption, distribution, metabolism, and excretion of the active ingredients in Pandemrix have not been performed.”
“Toxicology….There was evidence of an inflammatory response in haematology, clinical chemistry and pathological parameters. Increases in fibrinogen and white blood cell counts were noted in temporal association with the erythema and oedema noted on observing the rabbits. Relative to body weight, the spleen weight was increased in all groups compared to the control (7 – 41%)”
“Frequency and severity of fasciitis was higher in rabbits from the vaccine group. This toxicity was attributed to the adjuvant.”
“Minor changes indicative of an inflammatory response were noted in clinical chemistry and haematology in rabbits dosed with AS03 or with the trivalent influenza vaccine.”
(NB- some of these effect were claimed to be reversible over subsequent weeks, based on testing animals after a longer-time delay)
“Carcinogenicity…No carcinogenicity studies were conducted which is in line with the Note for Guidance on Preclinical pharmacological and toxicological testing of vaccines”
“Reproduction Toxicity….There was one unexpected death in a maternal rat: however, this was judged unrelated to the vaccine”
“Local tolerance….very slight oedema noted in one rabbit 3 hours after injection of the adjuvant AS03”
In the human trials, adverse events include:
Blood and lymphatic system disorders
Common: lymphadenopathy
Psychiatric disorders
Uncommon: insomnia
Nervous system disorders
Very common: headache
Uncommon: paraesthesia, somnolence, dizziness
Gastrointestinal disorders
Uncommon: gastro-intestinal symptoms (such as diarrhoea, vomiting, abdominal pain, nausea)
Skin and subcutaneous tissue disorders
Common: ecchymosis at the injection site, sweating increased
Uncommon: pruritus, rash
Musculoskeletal and connective tissue disorders
Very common: arthralgia, myalgia
General disorders and administration site conditions
Very common: induration, swelling, pain and redness at the injection site, fever, fatigue
Common: shivering, influenza like illness, injection site reactions (such as warmth, pruritus)
Uncommon: malaise
Mostly the reactions were worse for the sub-groups receiving adjuvanted formulations, and the rates were generally higher in the lower age group band 18-60 c.f. >60. NB the trial did not include anyone under 18 years old and the report details that there is no trial experience in children. This is of concern, as the CHMP report states:
“Pandemrix is commonly or very commonly associated with a range of local and systemic adverse reactions but these are not often of severe intensity and the safety profile would not preclude the use of the vaccine in healthy adults aged 18-60 years or > 60 years”
No trend analysis is provided in smaller age sub-sets i.e. whether there were more reactions in subjects aged 18-25 yrs cf. higher age brackets in the under 60’s group. If the trend is for reactions to be worse in line with decreasing age, this does not bode well for administration of the vaccine in babies, infants or adolescents.
Serious adverse events (SAE) were reported by ~30 patients – but these are not detailed, and were none were ‘considered’ to be related to the vaccination. There is also no data on co-administration of Pandemrix with other vaccines.
It is not clear how well or by what criteria GPs will assess someone to be a ‘healthy adult’ and therefore covered by the vaccine trial data. Would someone diagnosed with ME/CFS be considered healthy enough for the vaccine? It does not appear that they have been included in the studies, and therefore the adverse effects of the vaccination would be a complete unknown for them. Underlying mitochondrial dysfunction is known to be part of the ME/CFS pathology, and vaccines, as shown for instance in the case of Hannah Poling, can aggravate this problem.
GSK now plans to trial the vaccine in an additional 9,000 patients, but these patients will be monitored for a matter of days or weeks after their shots, so any kind of delayed hypersensitivity or rate of onset of autoimmune or other illness may not be picked up before a mass vaccination campaign begins.
To date there have only been 80 swine-flu related deaths in the UK in 2009 and in general, symptoms are not severe. It really must be considered whether it is safe or appropriate therefore to begin mass vaccinating populations with a fast-tracked vaccine with little or no testing or post-marketing surveillance in the majority of the target population, and especially the under-18’s. The only parties who stand to gain significantly from this vaccination programme at present, are the vaccine manufacturers and GPs surgeries who will receive a payment of £5.25 per dose of vaccine administered. Somewhat ironic, when you consider that 33% of nurses
surveyed and a staggering
60% of doctors have said that they would not be vaccinated themselves due to vaccine safety and efficacy concerns.
If it is not good enough for doctors and nurses, based on the mild symptoms, and fears of inadequate vaccine safety and efficacy then why should it be OK for anyone else? But blinded by the money and government dogma, no doubt the vaccines will be administered to millions of people unless they put up their own resistance.
In the end, it will be down to a well-informed public to ensure that H1N1 vaccines such as GSK’s Pandemrix, or more aptly ‘Pandorix’, are not let out of the box.
Lara, Health Advocate
28 September 2009

Go here for more.

About Clare Swinney

Interested in what is genuinely going on, not in the disinformation promoted as "truth" by the corrupt mainstream media. Please keep an open mind and do your own research. M.Sc. (Hons) from Auckland University. If you came to this site via the 'Silly Beliefs' disinformation website, please read my response to their article at the link: https://chemtrailsnorthnz.wordpress.com/2012/10/20/sillybeliefs-coms-lies-about-chemtrails-geo-engineering-exposed/
This entry was posted in Pandemic, Vaccines and tagged , , . Bookmark the permalink.

4 Responses to GSK’s Pandemrix Swine Flu Vaccine- Pandora’s Box Release

  1. Pandy Wang says:

    Thanks for the quick information. Actually I am looking for it. Here is my comments: Every decision has some risk to associate with. For instance, you will intake mercury by eating certain type of fish as well. The key is what will be the Relative Risk when you choose A instead of B. Could you provide some further information re 1) the NET RISK of taking this swine flu vaccine: The risk of serious adverse event (SAE) of vaccine minus the risk of severe consequence associated with swine flu in a population perspective. 2) how much mercury intake is too much? as this will give some perspective regarding the 5ug Thiomersal per dose. That will make your argument much solid. If the pron is much higher than the con, we should go for it. If not, we should not. We can not ban car just because many people are killed/disabled by car accidents.

    Thanks

    • Clare Swinney says:

      Pandy, if you look at the list of ingredients of the vaccine, there is a lot more to be concerned about than just mercury.
      The ingredient Polysorbate 80 is linked to causing sterility in rats. Refer: http://www.infonews.co.nz/news.cfm?l=1&t=0&id=28314
      As the article mentions squalene is also a controversial compound, shown by a number of researchers to induce autoimmune disease in animals and has been linked to illness in Gulf War Veterans.

      In addition, as journalist Wayne Madsen has pointed out, researchers believe the virus is mutating far too quickly for a vaccine to be of any use anyway. Please refer this interview with him on Russia Today:

      Also refer:
      Vaccines As Biological Weapons? Live Avian Flu Virus Placed In Baxter Vaccine Materials Sent to 18 Countries. http://www.infowars.com/vaccines-as-biological-weapons-live-avian-flu-virus-placed-in-baxter-vaccine-materials-sent-to-18-countries/

      The swine flu virus is producing very mild symptoms, so what is the point of taking a risky vaccine that Wayne Madsen points out will not be of any use anyway?

  2. Toby Lee says:

    There is substantial data suggesting that keeping your vitamin D levels up will protect you from H1N1 (Swine Flu) and colds and flu in general.
    Take a look at these two articles:

    August 2009-Vitamin D3 deficiency and its role in influenza
    http://archive.constantcontact.com/fs026/1102452079631/archive/1102685428884.html

    Sept 2009-More on Vitamin D3 and influenza
    http://archive.constantcontact.com/fs026/1102452079631/archive/1102728693089.html

    If the links don’t work, go to http://www.vitaminD3world.com and look under “In the News” This site offers a good newsletter on Vitamin D updates and recently launched a new micropill formulation of Vitamin D.

  3. David Cee says:

    Toby, there is far more to disease resistance than vitamin D. I haven’t had the flu or a cold for years & this is by ensuring the bulk of what I eat is not refined food & maintaining a happy attitude to life. People have a tendency to break things down to the smallest constituent parts (e.g. vit. D) instead of looking at the big picture.
    This is especially true of science & medicine.

    What puzzles me is why people even mention protection from H1N1 – it is mostly a mild form of the flu & as such should be treated with the contempt it & the promulgators of the H1N1 industry deserve.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s